David A. Siegel Rocket Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 10,845 shares of RCKT stock, worth $99,882. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,845
Previous 16,045
32.41%
Holding current value
$99,882
Previous $296,000
54.05%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding RCKT
# of Institutions
244Shares Held
108MCall Options Held
262KPut Options Held
159K-
Rtw Investments, LP New York, NY17.7MShares$163 Million3.63% of portfolio
-
Wellington Management Group LLP Boston, MA14MShares$129 Million0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.58MShares$60.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$57 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx5.2MShares$47.9 Million1.26% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $697M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...